SCHEMBL4699164

SCHEMBL4699164

CN(c1cccc(-c2ccnc3c([N+](=O)[O-])cnn23)c1)S(=O)(=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
MAPK1 P28482 1/20 0.41
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41
AOX1 Q06278 1/20 0.41
PDE3A Q14432 1/20 0.41
HSD17B1 P14061 3/20 0.40
HSD17B2 P37059 3/20 0.40
TLR8 Q9NR97 1/20 0.39
F2 P00734 2/20 0.39
CLK4 Q9HAZ1 2/20 0.38
MAP2K1 Q02750 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4701084 0.91 POLB (0.44) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL4703700 0.88 KDM4E (0.43) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL4703160 0.88 MAPK1 (0.45) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL4701061 0.86 KDM4E (0.42) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL4703709 0.86 KDM4E (0.46) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL4701446 0.85 KDM4E (0.42) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL4702947 0.85 ESR1 (0.43) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL1884765 0.83 KDM4E (0.61) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL4700623 0.81 KDM4E (0.52) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL4701436 0.80 CLK4 (0.56) KDM4ETLR8CLK4MAP2K1DYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648896-B1 7-SUBSTITUTED 3-NITRO-PYRAZOLO [1,5-A] PYRIMIDINES FERRER INT (ES) 2008-02-13 EP claimed
US-20070043064-A1 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines FERRER INTERNACIONAL S.A. (ES) 2007-02-22 US claimed
EP-1648896-A1 7-SUBSTITUTED 3-NITRO-PYRAZOLO [1,5-A] PYRIMIDINES FERRER INTERNACIONAL, S.A. (ES) 2006-04-26 EP claimed
WO-2005014596-A1 7-SUBSTITUTED 3-NITRO-PYRAZOLO `1,5-A! PYRIMIDINES FERRER INTERNACIONAL, S.A. (ES) 2005-02-17 WO claimed
EP-1648896-B1 7-SUBSTITUTED 3-NITRO-PYRAZOLO [1,5-A] PYRIMIDINES FERRER INT (ES) 2008-02-13 EP disclosed
US-20070043064-A1 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines FERRER INTERNACIONAL S.A. (ES) 2007-02-22 US disclosed
CN-1829720-A 7-substituted 3-nitro-pyrazolo '1,5-a! pyrimidines FERRER INT (ES) 2006-09-06 CN disclosed
EP-1648896-A1 7-SUBSTITUTED 3-NITRO-PYRAZOLO [1,5-A] PYRIMIDINES FERRER INTERNACIONAL, S.A. (ES) 2006-04-26 EP disclosed
WO-2005014596-A1 7-SUBSTITUTED 3-NITRO-PYRAZOLO `1,5-A! PYRIMIDINES FERRER INTERNACIONAL, S.A. (ES) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043064-A1 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines GABRB1, GABRA1, GABRB2 KDM4E 3514/4885GABRA1 2/4885GABRG2 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.